Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial - Chart
- Upturn Summary
- Highlights
- Valuation
- About
BBNX 
Beta Bionics, Inc. Common Stock (BBNX)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- 1Y
- 1M
- 1W
Upturn Advisory Summary
01/09/2026: BBNX (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
7 Analysts rated it
Limited analyst coverage, niche firm, research info may be scarce.
1 Year Target Price $32.6
1 Year Target Price $32.6
| 4 | Strong Buy |
| 1 | Buy |
| 2 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -2.79% | Avg. Invested days 32 | Today’s Advisory WEAK BUY |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 01/09/2026 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 1.41B USD | Price to earnings Ratio - | 1Y Target Price 32.6 |
Price to earnings Ratio - | 1Y Target Price 32.6 | ||
Volume (30-day avg) 7 | Beta - | 52 Weeks Range 8.89 - 32.71 | Updated Date 01/9/2026 |
52 Weeks Range 8.89 - 32.71 | Updated Date 01/9/2026 | ||
Dividends yield (FY) - | Basic EPS (TTM) -1.94 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin -87.89% | Operating Margin (TTM) -62.54% |
Management Effectiveness
Return on Assets (TTM) -20.08% | Return on Equity (TTM) -47.52% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 1187347945 | Price to Sales(TTM) 15.9 |
Enterprise Value 1187347945 | Price to Sales(TTM) 15.9 | ||
Enterprise Value to Revenue 13.41 | Enterprise Value to EBITDA - | Shares Outstanding 44024631 | Shares Floating 24095561 |
Shares Outstanding 44024631 | Shares Floating 24095561 | ||
Percent Insiders 10.42 | Percent Institutions 110.53 |
Upturn AI SWOT
Beta Bionics, Inc. Common Stock
Company Overview
History and Background
Beta Bionics, Inc. is a clinical-stage medical device company focused on developing the 'iLet' bionic pancreas system. Founded in 2015 by a group of researchers and patients, the company's mission is to revolutionize diabetes management by creating an automated insulin delivery system that significantly reduces the burden of managing Type 1 diabetes. A key milestone was the initiation of pivotal clinical trials for the iLet system.
Core Business Areas
- Bionic Pancreas System Development: Beta Bionics is dedicated to the research, development, and eventual commercialization of its flagship product, the iLet bionic pancreas. This system aims to automate insulin delivery for individuals with Type 1 diabetes, responding to real-time glucose readings.
Leadership and Structure
Beta Bionics, Inc. is led by a management team with expertise in medical devices, diabetes technology, and business operations. The company operates as a privately held entity, with a board of directors overseeing strategic direction.
Top Products and Market Share
Key Offerings
- iLet Bionic Pancreas System: The iLet is a closed-loop insulin delivery system designed to automatically adjust insulin doses based on continuous glucose monitoring (CGM) data. It utilizes advanced algorithms to predict glucose trends and deliver the optimal amount of insulin, aiming to reduce hypoglycemia and hyperglycemia. The system is currently in clinical trials. There is no publicly available market share data as the product is not yet commercially available. Competitors in the automated insulin delivery space include Medtronic (MiniMed series), Tandem Diabetes Care (t:slim X2), and Insulet (Omnipod).
Market Dynamics
Industry Overview
The diabetes technology market, particularly the automated insulin delivery (AID) segment, is experiencing rapid innovation and growth. Driven by increasing rates of diabetes, advancements in sensor technology, and a demand for more convenient and effective management solutions, the industry is highly competitive and dynamic.
Positioning
Beta Bionics is positioning the iLet system as a simpler, more intuitive, and highly effective solution for Type 1 diabetes management, aiming to improve quality of life for patients by reducing the cognitive burden of diabetes. Its 'pocket-sized' design and algorithm focus are key differentiators. Its current position is that of a clinical-stage developer, seeking regulatory approval.
Total Addressable Market (TAM)
The global diabetes device market is substantial and growing, with the AID segment representing a significant portion. The TAM for automated insulin delivery systems is estimated to be in the tens of billions of dollars annually. Beta Bionics is targeting the Type 1 diabetes population, a subset of this larger market, with its iLet system.
Upturn SWOT Analysis
Strengths
- Innovative bionic pancreas technology (iLet system)
- Focus on simplifying diabetes management
- Experienced leadership team in medical devices and diabetes
- Strong clinical trial results to date
Weaknesses
- Not yet commercially available, reliance on regulatory approval
- Limited brand recognition compared to established players
- Potential for high development and manufacturing costs
- Dependence on key technological components and partnerships
Opportunities
- Growing demand for automated diabetes management solutions
- Potential for expansion into other diabetes-related technologies
- Partnerships with CGM manufacturers and healthcare providers
- Increasing awareness and adoption of advanced diabetes technology
Threats
- Intense competition from established medical device companies
- Regulatory hurdles and lengthy approval processes
- Reimbursement challenges from payers
- Rapid technological advancements by competitors
- Potential for adverse events or product recalls
Competitors and Market Share
Key Competitors
- Medtronic (MDT)
- Tandem Diabetes Care (TNDM)
- Insulet Corporation (PODD)
Competitive Landscape
Beta Bionics faces strong competition from established players with existing customer bases and proven product lines. Its advantage lies in its novel algorithm and simplified user experience, but it must overcome the market presence of its competitors. The market is characterized by continuous innovation and a focus on user-centric design and efficacy.
Growth Trajectory and Initiatives
Historical Growth: Beta Bionics' growth has been characterized by its progress in research and development, successful clinical trial phases, and securing significant investment to advance its technology. Its growth is tied to the progression of the iLet system towards commercialization.
Future Projections: Future growth projections for Beta Bionics are dependent on the successful regulatory approval and market adoption of the iLet bionic pancreas system. Projections would typically be made by investors based on market potential and the company's execution capabilities.
Recent Initiatives: Key recent initiatives include the progression of pivotal clinical trials for the iLet system, seeking FDA approval, and potentially establishing manufacturing and distribution partnerships.
Summary
Beta Bionics is a promising clinical-stage company focused on revolutionizing Type 1 diabetes management with its iLet bionic pancreas. Its innovative technology and clear mission are strong assets. However, it faces significant hurdles including regulatory approval, intense competition from established players, and the need for substantial capital to scale. Success hinges on demonstrating superior efficacy and user experience to gain market traction.
Similar Stocks
Sources and Disclaimers
Data Sources:
- Company website and press releases (publicly available information)
- Industry reports on diabetes technology market
- Financial news outlets reporting on medical device companies
Disclaimers:
This analysis is based on publicly available information and general market knowledge. Beta Bionics, Inc. is a privately held company, and detailed financial data is not disclosed. Market share figures for competitors are estimates. This information is for informational purposes only and does not constitute investment advice. Investors should conduct their own due diligence.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Beta Bionics, Inc. Common Stock
Exchange NASDAQ | Headquaters Irvine, CA, United States | ||
IPO Launch date 2025-01-30 | President, CEO & Director Mr. Sean T. Saint PE | ||
Sector Healthcare | Industry Medical Devices | Full time employees 404 | Website https://www.betabionics.com |
Full time employees 404 | Website https://www.betabionics.com | ||
Beta Bionics, Inc., a commercial-stage medical device company, engages in the design, development, and commercialization of solutions to enhance the health and quality of life of insulin-requiring people with diabetes. It offers iLet Bionic Pancreas, an insulin delivery device for the treatment of type 1 diabetes in adults and children six years of age and older. The company is developing Patch Pump, an insulin pump that is designed to adhere directly to the skin and administer insulin without the need for tubing; Bihormonal iLet, which combines automated delivery of insulin and glucagon; and iLet to treat people with insulin-dependent type-2 diabetes. It has collaboration and license agreement with Xeris Pharmaceuticals, Inc. (Xeris) to develop and commercialize a pump-compatible glucagon formulation; and development and commercialization agreement with Abbott Diabetes Care Inc. to develop and commercialize an automated insulin delivery system. The company was incorporated in 2015 and is based in Irvine, California.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.